As of May 2, 2024, the Biomarin Pharmaceutical stock's PE ratio is 76.88. This results from the current EPS of $1.09 and stock price of $83.8. The P/E ratio has a decrease of 35% from the past four quarters average of 117.5.
The PE ratio of Biomarin Pharmaceutical has averaged 211.22 over the last five years. The current PE ratio of 76.88 is 64% below the historical average. Over the past five years, BMRN's PE ratio was at its highest in the Sep 2021 quarter at 1,288.17, when the stock price was $77.29 and the EPS was $0.06. The lowest value was in the Sep 2020 quarter, when it reached 16.15 with a price of $76.08 and an EPS of $4.71.
Maximum annual decrease: -20.44% in 2023
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 108.34 | -20.44% |
| 2022 | 136.17 | N/A |
| 2021 | N/A | N/A |
| 2020 | 18.58 | N/A |
| 2019 | N/A | N/A |
| 2018 | N/A | N/A |
| 2017 | N/A | N/A |
| 2016 | N/A | N/A |
| 2015 | N/A | N/A |
| 2014 | N/A | N/A |
BMRN's current P/E ratio is below the 3, 5 and 10-year averages.
Compared to its peer stock CPRX, BMRN's PE ratio stands higher.
| Stock name | PE ratio | Market cap |
|---|---|---|
| CPRX Catalyst Pharmaceuticals Inc | 22.42 | $1.77B |
| BMRN Biomarin Pharmaceutical Inc | 76.88 | $15.91B |
| RARE Ultragenyx Pharmaceutical Inc | N/A | $3.56B |
| SGMO Sangamo Therapeutics Inc | N/A | $93.39M |
| FOLD Amicus Therapeutics Inc | N/A | $3.08B |
| ESPR Esperion Therapeutics Inc | N/A | $381.21M |
The price to earnings ratio for BMRN stock as of May 2, 2024, stands at 76.88.
The 3-year average PE ratio for BMRN stock is 274.24.
The 5-year average PE ratio for BMRN stock is 211.22.
Over the last five years, the quarterly PE ratio reached a historic high of 1,288.17 in the Sep 2021 quarter.
BMRN's price to earnings ratio is currently 64% below its 5-year historical average.
BMRN's PE ratio of 76.88 is considered high because the company's stock price is trading at a higher multiple of earnings.
To determine the PE ratio, divide the most recent stock price by the TTM earnings per share (EPS). As of today (May 2, 2024), Biomarin Pharmaceutical's stock price is $83.8. The earnings per share for the trailing twelve months (TTM) ending Mar 2024 is $1.09. Therefore, Biomarin Pharmaceutical's P/E ratio for today is 76.88. PE RATIO(76.88) = STOCK PRICE($83.8) / TTM EPS($1.09)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.